AstraZeneca drug reduces lung disease flare-ups in late-stage trials

Today we feature data from studies being presented at the ongoing European Respiratory Society Congress in Barcelona.

Reuters • 11 hours ago

AstraZeneca COPD data back Citi's $7b peak sales case

AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) drew Citi's backing after tozorakimab trial results, supporting an upside case of at least $7 billion in peak sales, roughly twice consensus. Behind the bullish call, phase III data presented at the European Respiratory Society meeting showed tozorakimab reduced flare-ups in chronic obstructive pulmonary disease (COPD).

Proactive Investors • 9 hours ago

AstraZeneca's COPD drug scores two late-stage trial wins as full data boosts blockbuster hopes

AstraZeneca released full results from two successful late-stage trials on its experimental drug for chronic obstructive pulmonary disease. The detailed data reinforces hopes that the product could be a breakthrough treatment for COPD and reach AstraZeneca's peak annual sales forecast of more than $5 billion for the drug.

CNBC • Sep 8, 2026

AstraZeneca's cancer drug combo hits main survival goal in late-stage trial

AstraZeneca said ​on Tuesday its ‌cancer drug Imfinzi ​combined ​with Amgen's targeted ⁠immunotherapy ​Imdelltra ​significantly improved overall survival ​in ​first-line extensive-stage ‌small ⁠cell lung cancer in ​a ​late-stage ⁠trial.

Reuters • Sep 8, 2026

Amgen Falls 10% as Novartis Trial Failure Clouds a Cholesterol Drug Class; NVS Stock Drops 14%

A failed cholesterol trial from Novartis (NYSE:NVS | NVS Price Prediction) is dragging the Lp(a) drug class lower and hitting Amgen (NASDAQ:AMGN) harder than any large-cap peer in Tuesday trading.

24/7 Wall Street • Sep 8, 2026

AstraZeneca PLC (AZN) Presents at European Respiratory Society (ERS) Congress Transcript

AstraZeneca PLC (AZN) Presents at European Respiratory Society (ERS) Congress Transcript

Seeking Alpha • Sep 8, 2026

Tozorakimab demonstrated statistically significant and highly clinically meaningful reduction in COPD exacerbations in OBERON and TITANIA Phase III trials

WILMINGTON, Del.--(BUSINESS WIRE)--Full results from the positive Phase III OBERON and TITANIA trials showed that tozorakimab is the first biologic to demonstrate statistically significant and highly clinically meaningful efficacy in reducing moderate and severe exacerbations in a broad population of patients with chronic obstructive pulmonary disease (COPD) still experiencing exacerbations while on inhaled standard of care.1,2 The trials included former and current smokers, and patients across.

Business Wire • Sep 8, 2026

AstraZeneca Says Lung-Disease Drug Shows Benefits Across Patient Groups

AstraZeneca said its new drug for COPD showed benefits across a broad patient population in late-stage clinical trials, boosting a medicine the company expects to generate multibillion-dollar sales.

WSJ • Sep 8, 2026

Citi backs AstraZeneca sentiment boost after Etcamah wins accelerated FDA approval

Citi has flagged AstraZeneca PLC's (LSE:AZN, NASDAQ:AZN) accelerated approval for Etcamah, known chemically as camizestrant, as a meaningful sentiment driver for the shares. The oral selective oestrogen receptor degrader has been cleared by the US Food and Drug Administration in combination with a CDK4/6 inhibitor for hormone receptor positive, HER2 negative metastatic breast cancer.

Proactive Investors • Sep 7, 2026

AstraZeneca Secures FDA Nod for New Breast Cancer Therapy Etcamah

AZN's Etcamah wins accelerated FDA approval for certain advanced breast cancer patients, backed by a 56% risk reduction in progression or death.

Zacks Investment Research • Sep 7, 2026